INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS
    1.
    发明申请
    INDAZOLES AS GLUCOCORTICOID RECEPTOR LIGANDS 有权
    INDAZOLES作为GLUCOCORTICOID受体配体

    公开(公告)号:US20090074675A1

    公开(公告)日:2009-03-19

    申请号:US11910935

    申请日:2006-04-12

    摘要: A compound of formula (I): wherein A1 represents 2,3-dihydro-1-benzofuran-7-yl, 5-fluoro-2-methoxy-phenyl or 5-fluoro-2-hydroxy-phenyl; X represents —C(R3)— or nitrogen; when X represents —C(R3)—, R2 represents hydrogen and R1 represents fluorine, R3 represents hydrogen or fluorine, when X represents —C(R3)— and R2 and R1 each represent hydrogen, R3 represents hydrogen, hydroxy, methoxy or fluorine, when X represents —C(R3)— and R2 represents hydroxy, methoxy, —CO2CH3 or —CO2CH2CH3, R1 and R3 each represent hydrogen, when X represents nitrogen, R1 and R2 each represent hydrogen; and Y represents H or methyl; or a physiologically functional derivative thereof.

    摘要翻译: 式(I)的化合物:其中A1表示2,3-二氢-1-苯并呋喃-7-基,5-氟-2-甲氧基 - 苯基或5-氟-2-羟基 - 苯基; X表示-C(R 3) - 或氮; 当X表示-C(R3) - 时,R2表示氢,R1表示氟,R3表示氢或氟,当X表示-C(R3) - 且R2和R1各自表示氢时,R3表示氢,羟基,甲氧基或氟 当X表示-C(R 3) - 且R 2表示羟基,甲氧基,-CO 2 CH 3或-CO 2 CH 2 CH 3时,R 1和R 3各自表示氢,当X表示氮时,R 1和R 2各自表示氢; Y表示H或甲基; 或其生理功能衍生物。

    1,7-Naphthyridines as Pde4 Inhibitors
    4.
    发明申请
    1,7-Naphthyridines as Pde4 Inhibitors 审中-公开
    1,7-萘乙酸作为Pde4抑制剂

    公开(公告)号:US20080146563A1

    公开(公告)日:2008-06-19

    申请号:US11908188

    申请日:2006-03-16

    CPC分类号: C07D471/04

    摘要: There are provided according to the invention novel compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof: wherein R1 is selected from the group consisting of C1-4alkyl, C4-6cycloalkyl(CH2)m—, methoxyC2-4alkyl, HOCH2CH2—, R3(O)2S(CH2)2—, R5R4NCO(CH2)n—, and heterocyclyl(CH2)m— wherein any nitrogen heteroatom of the heterocyclyl radical may be unsubstituted or substituted by methyl; R2 is hydrogen or methyl; R3 is methyl or NH2; R4-5 independently represent methyl, m is 0, 1 or 2; and n is 1 or 2; or R1 and R2 together with the nitrogen atom to which they are attached may form a heterocyclyl ring, which may be unsubstituted or substituted by one or two substituents selected from the group consisting of; methyl, ═O and (CH3)2N—.

    摘要翻译: 根据本发明提供新的式(I)化合物及其药学上可接受的盐和溶剂合物:其中R 1选自C 1-4烷基, 烷基,C 4-6环烷基(CH 2 CH 2)m - ,甲氧基C 2-4烷基, (O)2 S 2(CH 2)2 - - - - (CH 2) R 2,R 5,R 5,R 5,N 2,N 2, 和杂环基(CH 2 CH 2)m - ,其中杂环基的任何氮杂原子可以是未取代的或被甲基取代; R 2是氢或甲基; R 3是甲基或NH 2; R 4-5独立地表示甲基,m是0,1或2; n为1或2; 或R 1和R 2与它们所连接的氮原子一起可以形成杂环基环,其可以是未取代的或被一个或两个选自以下的取代基取代: 组成; 甲基,-O和(CH 3)2 N - 。

    Chemical Compounds
    6.
    发明授权
    Chemical Compounds 失效
    化学化合物

    公开(公告)号:US06455510B1

    公开(公告)日:2002-09-24

    申请号:US09530573

    申请日:2000-06-15

    IPC分类号: A61K3170

    CPC分类号: C07H19/16

    摘要: A compound of formula (I) which is an agonist at the adenosine A1 receptor wherein R2 represents C1-3alkyl, halogen or hydrogen; R3 represents a fluorinated straight or branched alkyl group of 1-6 carbon atoms and salts and solvates thereof, in particular, physiologically acceptable solvates and salts thereof. These compounds are agonists at the adenosine A1 receptor.

    摘要翻译: 式(I)化合物,其为腺苷A1受体的激动剂,其中R2表示C1-3烷基,卤素或氢; R3表示1-6个碳原子的氟化直链或支链烷基及其盐和溶剂化物,特别是其生理上可接受的溶剂合物及其盐。 这些化合物是腺苷A1受体的激动剂。

    Indazoles as glucocorticoid receptor ligands
    8.
    发明授权
    Indazoles as glucocorticoid receptor ligands 有权
    吲哚类作为糖皮质激素受体配体

    公开(公告)号:US08093281B2

    公开(公告)日:2012-01-10

    申请号:US11910935

    申请日:2006-04-12

    IPC分类号: A61K31/416 C07D231/56

    摘要: A compound of formula (I): wherein A1 represents 2,3-dihydro-1-benzofuran-7-yl, 5-fluoro-2-methoxy-phenyl or 5-fluoro-2-hydroxy-phenyl; X represents —C(R3)— or nitrogen; when X represents —C(R3)—, R2 represents hydrogen and R1 represents fluorine, R3 represents hydrogen or fluorine, when X represents —C(R3)— and R2 and R1 each represent hydrogen, R3 represents hydrogen, hydroxy, methoxy or fluorine, when X represents —C(R3)— and R2 represents hydroxy, methoxy, —CO2CH3 or —CO2CH2CH3, R1 and R3 each represent hydrogen, when X represents nitrogen, R1 and R2 each represent hydrogen; and Y represents H or methyl; or a physiologically functional derivative thereof.

    摘要翻译: 式(I)的化合物:其中A1表示2,3-二氢-1-苯并呋喃-7-基,5-氟-2-甲氧基 - 苯基或5-氟-2-羟基 - 苯基; X表示-C(R 3) - 或氮; 当X表示-C(R3) - 时,R2表示氢,R1表示氟,R3表示氢或氟,当X表示-C(R3) - 且R2和R1各自表示氢时,R3表示氢,羟基,甲氧基或氟 当X表示-C(R 3) - 且R 2表示羟基,甲氧基,-CO 2 CH 3或-CO 2 CH 2 CH 3时,R 1和R 3各自表示氢,当X表示氮时,R 1和R 2各自表示氢; Y表示H或甲基; 或其生理功能衍生物。

    1,7-Naphthyridines
    9.
    发明申请
    1,7-Naphthyridines 审中-公开
    1,7-萘啶

    公开(公告)号:US20090270444A1

    公开(公告)日:2009-10-29

    申请号:US11718892

    申请日:2005-11-17

    CPC分类号: C07D471/04

    摘要: There are provided according to the invention novel compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein: R1 is phenyl which may be unsubstituted or substituted by one or two substituents selected from fluorine, chlorine, C1-2alkoxy-, —CN; phenyl fused to a 5-membered saturated ring containing one oxygen atom; pyridinyl which may be unsubstituted or substituted by one or two substituents selected from fluorine or chlorine; or C-linked pyrazolyl which may be unsubstituted or substituted by the substituent C1-2alkyl; R2 is C1-4alkyl; R3 is C1-2alkyl; and n is 0, 1 or 2.

    摘要翻译: 根据本发明,提供新的式(I)化合物及其药学上可接受的盐和溶剂化物,其中:R1是可以是未取代的或被一个或两个选自氟,氯,C 1-2烷氧基 - , - CN; 与含有一个氧原子的5元饱和环稠合的苯基; 吡啶基,其可以是未取代的或被一个或两个选自氟或氯的取代基取代; 或C连接的吡唑基,其可以是未取代的或被取代基C 1-2烷基取代; R2是C1-4烷基; R3是C1-2烷基; n为0,1或2。

    Chemical compounds
    10.
    发明授权
    Chemical compounds 失效
    化合物

    公开(公告)号:US06740644B2

    公开(公告)日:2004-05-25

    申请号:US10373064

    申请日:2003-02-26

    IPC分类号: A61K3170

    CPC分类号: C07H19/16 Y02P20/55

    摘要: A compound of formula (I), wherein R2 represents C1-3alkyl, halogen or hydrogen; R3 represents straight or branched alkyl group of 1-6 carbon atoms; with the proviso that, when R3 represents C1-3alkyl, R2 represents C1-3alkyl, R1 cannot represent phenyl optionally substituted by one or more substituents selected from halogen, C1-3alkyl, trifluoromethyl, nitro, cyano, —CO2Rc, —CONRcRd, —CORc, —SORe, —SO2Re, —SO3H, —SO2NRcRd, —ORc, —NHSO2Re, —NHCORc and —NRcRd; and salts and solvates thereof, in particular, physiologically acceptable solvates and salts thereof. These compounds are agonists at the Adenosine A1 receptor.

    摘要翻译: 式(I)的化合物,其中R 2表示C 1-3烷基,卤素或氢; R 3表示1-6个碳原子的直链或支链烷基; 条件是当R 3表示C 1-3烷基时,R 2表示C 1-3烷基,R 1不能表示任选被一个或多个选自卤素,C 1-3烷基,三氟甲基,硝基, 氰基,-CO 2 R c,-CONR c R d,-COR c,-SOR e,-SO 2 R e,-SO 3 H,-SO 2 NR c R d, OR c,-NHSO 2 R e,-NHCOR c和-NR c R d; 特别是其生理上可接受的溶剂合物及其盐。 这些化合物是腺苷A1受体的激动剂。